112 related articles for article (PubMed ID: 27648713)
21. Endometrial cancer after tamoxifen treatment: a descriptive study of 25 breast cancer patients who subsequently developed endometrial cancer.
Peters-Engl C; Medl M; Danmayr E; Mirau M; Alth G; Leodolter S
Anticancer Res; 1996; 16(5B):3241-6. PubMed ID: 8920798
[TBL] [Abstract][Full Text] [Related]
22. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
Cheng WF; Lin HH; Torng PL; Huang SC
Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
[TBL] [Abstract][Full Text] [Related]
23. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
24. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
25. Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer : comparison of cohorts treated with and without tamoxifen.
Saadat M; Truong PT; Kader HA; Speers CH; Berthelet E; McMurtrie E; Olivotto IA
Cancer; 2007 Jul; 110(1):31-7. PubMed ID: 17510927
[TBL] [Abstract][Full Text] [Related]
26. Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.
Siegelmann-Danieli N; Kurnik D; Lomnicky Y; Vesterman-Landes J; Katzir I; Bialik M; Loebstein R
Breast Cancer Res Treat; 2011 Jan; 125(2):505-10. PubMed ID: 20593233
[TBL] [Abstract][Full Text] [Related]
27. Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials.
Petrelli F; Coinu A; Cabiddu M; Ghilardi M; Lonati V; Barni S
Breast Cancer Res Treat; 2013 Jul; 140(2):233-40. PubMed ID: 23860926
[TBL] [Abstract][Full Text] [Related]
28. Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma.
Pierce SR; Stine JE; Gehrig PA; Havrilesky LJ; Secord AA; Nakayama J; Snavely AC; Moore DT; Kim KH
Gynecol Oncol; 2017 Mar; 144(3):531-535. PubMed ID: 28062116
[TBL] [Abstract][Full Text] [Related]
29. Clinico-pathology and prognosis of endometrial cancer in patients previously treated for breast cancer, with or without tamoxifen: a comparative study in 363 patients.
Ngô C; Brugier C; Plancher C; de la Rochefordière A; Alran S; Féron JG; Malhaire C; Scholl S; Sastre X; Rouzier R; Fourchotte V;
Eur J Surg Oncol; 2014 Oct; 40(10):1237-44. PubMed ID: 25086993
[TBL] [Abstract][Full Text] [Related]
30. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?
Slomovitz BM; Sun CC; Ramirez PT; Bodurka DC; Diaz P; Lu KH
Obstet Gynecol; 2004 Aug; 104(2):255-60. PubMed ID: 15291996
[TBL] [Abstract][Full Text] [Related]
31. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
[TBL] [Abstract][Full Text] [Related]
32. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
33. Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy.
Nordenskjöld A; Fohlin H; Rosell J; Bengtsson NO; Fornander T; Hatschek T; Lindman H; Malmström P; Rydén L; Wallgren A; Stål O; Nordenskjöld B
Breast; 2023 Oct; 71():63-68. PubMed ID: 37517154
[TBL] [Abstract][Full Text] [Related]
34. Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients.
Bria E; Ciccarese M; Giannarelli D; Cuppone F; Nisticò C; Nuzzo C; Natoli G; Fabi A; Terzoli E; Cognetti F; Carlini P
Cancer Treat Rev; 2006 Aug; 32(5):325-32. PubMed ID: 16766125
[TBL] [Abstract][Full Text] [Related]
35. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
Swerdlow AJ; Jones ME;
J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574
[TBL] [Abstract][Full Text] [Related]
36. Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype.
Alramadhan M; Ryu JM; Rayzah M; Nam SJ; Kim SW; Yu J; Lee SK; Bae SY; Park S; Paik HJ; Lee JE
Breast; 2016 Dec; 30():111-117. PubMed ID: 27697675
[TBL] [Abstract][Full Text] [Related]
37. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy.
Barakat RR; Gilewski TA; Almadrones L; Saigo PE; Venkatraman E; Hudis C; Hoskins WJ
J Clin Oncol; 2000 Oct; 18(20):3459-63. PubMed ID: 11032585
[TBL] [Abstract][Full Text] [Related]
38. Characteristics and survival of patients with metachronous or synchronous double primary malignancies: breast and thyroid cancer.
Zhang L; Wu Y; Liu F; Fu L; Tong Z
Oncotarget; 2016 Aug; 7(32):52450-52459. PubMed ID: 27223440
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Adjuvant Radiation Therapy Alone Versus Radiation Therapy and Endocrine Therapy in Elderly Women With Early-Stage, Hormone Receptor-Positive Breast Cancer Treated With Breast-Conserving Surgery.
Murphy CT; Li T; Wang LS; Obeid EI; Bleicher RJ; Eastwick G; Johnson ME; Hayes SB; Weiss SE; Anderson PR
Clin Breast Cancer; 2015 Oct; 15(5):381-9. PubMed ID: 25861716
[TBL] [Abstract][Full Text] [Related]
40. The ATAC adjuvant breast-cancer trial: six-year results of the endometrial subprotocol.
Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Clack G; Bianco AR;
J Obstet Gynaecol; 2010; 30(6):596-604. PubMed ID: 20701510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
